Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koh, Myeong Seok | - |
dc.contributor.author | Kim, Won Seog | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Yoon, Dok Hyun | - |
dc.contributor.author | Lee, Soon Il | - |
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Song, Moo Kon | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Kwon, Jung Hye | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Do, Yong Rok | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Kim, Hyo Jin | - |
dc.date.available | 2020-02-28T07:45:53Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-10 | - |
dc.identifier.issn | 0925-5710 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10099 | - |
dc.description.abstract | Even though local stage (Ann Arbor stage I/II) marginal zone lymphoma (MZL) is well controlled with local treatment-based therapy, no data exist on the role of additional chemotherapy after local treatment for stage I/II MZL. Patients with biopsy-confirmed Ann Arbor stage I/II MZL (n = 210) were included for analysis in this study. Of these, 180 patients (85.7 %) were stage I and 30 (14.3 %) were stage II. Most patients (n = 182, 86.7 %) were treated with a local modality including radiation therapy or surgery and 28 (13.3 %) received additional systemic chemotherapy after local treatment. The overall response rate was 98.3 % (95 % CI 96-100 %), with 187 complete responses and 20 partial responses. In the local treatment group, the mean progression-free survival (PFS) was 147.4 months (95 % CI 126.7-168.1 months) and the overall survival (OS) was 188.2 months (95 % CI 178.8-197.7 months). In the additional chemotherapy group, the mean PFS was 103.4 months (95 % CI 84.9-121.9 months) and the OS was 137.3 months (95 % CI 127.9-146.7 months). There was no difference between the two groups in OS (p = 0.836) and PFS (p = 0.695). Local stage MZL has a good clinical course and is well controlled with a local treatment modality without additional chemotherapy. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER JAPAN KK | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF HEMATOLOGY | - |
dc.subject | B-CELL LYMPHOMA | - |
dc.subject | TISSUE LYMPHOMA | - |
dc.subject | MALT | - |
dc.subject | DISEASE | - |
dc.subject | UPDATE | - |
dc.title | Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000362673700006 | - |
dc.identifier.doi | 10.1007/s12185-015-1845-6 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF HEMATOLOGY, v.102, no.4, pp.420 - 425 | - |
dc.identifier.scopusid | 2-s2.0-84951570615 | - |
dc.citation.endPage | 425 | - |
dc.citation.startPage | 420 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF HEMATOLOGY | - |
dc.citation.volume | 102 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Hong, Junshik | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Marginal zone | - |
dc.subject.keywordAuthor | B cell lymphoma | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Local stage | - |
dc.subject.keywordPlus | B-CELL LYMPHOMA | - |
dc.subject.keywordPlus | TISSUE LYMPHOMA | - |
dc.subject.keywordPlus | MALT | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | UPDATE | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.